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Purpose: When compared with carotid endarterectomy (CEA), percutaneous carotid angioplasty with stent replacement
(CAS) is a less invasive technique in the treatment of carotid stenosis. However, periprocedural hemodynamic instability
still remains a challenge. This instability might lead to myocardial damage, which is now measured accurately by using
cardiac troponin I (CTnI).
Methods: This study was designed to compare the periprocedural variation of CTnI in 150 consecutive patients scheduled
to undergo CEA (n  75) or CAS (n  75). The levels of CTnI were measured until the third postoperative day in all
patients. Short-term (1 month) and long-term (up to 5 years) postoperative cardiac outcome were assessed by means of
chart review, regular follow-ups, and telephone calls.
Results: There was not any statistically significant difference between the 2 groups regarding the demographic character-
istics and preprocedural medical status. The incidence of increase of CTnI (>0.5 ng/mL) was significantly higher in the
CEA group (13%) compared with that in the CAS group (1%; P  .001). During the acute postprocedural period, the
CAS group was significantly more prone to hypotension, requiring vasopressor therapy, whereas the CEA group had
more hypertension, necessitating hypotensive medications (P < .001). At 5 years, the overall incidence of major cardiac
complications (nonfatal myocardial infarction and death related to cardiac origin) was significantly more frequent in the
CEA group (20% vs 5%, P < .01).
Conclusion: The results of our study suggest that CAS yielded less myocardial damage in the short and long term when
compared with CEA. Larger randomized multicenter trials with long-term outcomes are necessary to confirm our
findings. ( J Vasc Surg 2005;41:769-74.)Carotid angioplasty and stent placement (CAS) has
been introduced as an alternative to surgical carotid endar-
terectomy (CEA) for the treatment of carotid artery steno-
sis.1-7 Although it is a less invasive percutaneous procedure,
hemodynamic instability is reported as being as frequent if
not higher than in CEA.8-10 This instability might be
related to the triggering of baroreflex after balloon dilata-
tion, stent delivery in the carotid sinus region, or both.8,9
Cardiac troponin I (CTnI) is a reliable marker of myocar-
dial injury in patients undergoing vascular surgery.11-13
Moreover, its use in predicting short-term and midterm
cardiac outcome in this population has been verified in 2
studies.12,14 A cutoff value of 1.5 ng/mL is sensitive and
specific for myocardial infarction (MI), even in the postop-
erative period, whereas values of between 0.5 and 1.5 ng/
mL are observed in unstable angina and are considered to
be the expression of myocardial ischemia or more limited
myocardial damage.2 To our knowledge, no study has
reported the periprocedural variation of this enzyme in a
group of consecutive patients undergoing CAS. This study
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doi:10.1016/j.jvs.2005.02.017was designed primarily to measure CTnI variation and
other cardiac complications after this procedure and com-
pare the results with those of a similar group of consecutive
patients scheduled for CEA. The second purpose of this
study was to assess prospectively the long-term cardiac
outcomes (up to 5 years) in both groups of patients.
METHODS
Patients. From July 1998 through December 1999,
150 consecutive patients undergoing elective CAS or sur-
gical CEA were prospectively included in the study, which
was conducted in a single university hospital. Patients hav-
ing renal dysfunction or undergoing emergency procedures
were excluded.
Exposure variable: CTnI. CTnI was assessed after
the procedure (1-3 hours) in the postanesthesia care unit
and on days 1, 2, and 3 postoperatively. No further mea-
surements were made if the results of these 4 analyses
remained normal. This sample-taking schedule was chosen
according to previous findings.15 Postoperative cardiac
events were assessed by means of clinical examination and
electrocardiography (ECG) until patient discharge.
The CTnI concentrations were determined by using an
immunoenzymofluorometric assay on a Stratus analyzer
(Dade, Massy, France). At the time of the study, the
detection limit of the immunoassay was 0.1 ng/mL. A
CTnI value of greater than 1.5 ng/mL associated or not
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of between 0.5 and 1.5 ng/mL were considered myocar-
dial ischemia.12,16
Data collection and follow-up. Clinical data were
prospectively collected and recorded during the patients’
hospitalizations. Long-term follow-up was assessed by
means of a systematic clinical review of patients by the
surgical team from 1 month to 5 years postoperatively. For
the accuracy of the clinical data assessment, all patients or
the family, except those who were lost to follow-up, were
interviewed by telephone. The interview was conducted by
2 independent investigators who were not aware of the
initial procedure. Any significant clinical events were noted.
All cardiology follow-ups were investigated and recorded.
This phase of the study lasted fromMarch through Decem-
ber 2003.
The clinical end points were major and minor cardiac
events. In the group of patients who died during the study
time frame, the cause of death was classified as cardiac or
noncardiac (including all other causes). Cardiac death was
defined by the occurrence at the time of death of MI, heart
failure, arrhythmia, and/or sudden death that was not
explained by another cause.
Late cardiac events were classified as major or minor.
Major cardiac events included nonfatal MI and cardiac
death. If cardiac death occurred at a different time point
after a nonfatal MI, only cardiac death was counted. Other
cardiac events included episodes of congestive heart failure,
coronary revascularization, valvular replacements, su-
praventricular and ventricular arrhythmia, and the need for
a pacemaker.
Anesthetic and surgical management. The choice
between stenting and endarterectomy was mostly based on
the anatomic evaluation of the carotid bifurcation. Angio-
plasty was performed in cases of healthy aortic arch, no
severe angulations of the common carotid arteries, and
absence of any floating thrombus or circular calcification
within the carotid stenosis. In the angioplasty group pa-
tients were informed of the investigative nature of the
technique and signed an informed consent form.
All procedures (CEA and CAS) were performed in an
operating room equipped with a radiologic C arm by a
single team of vascular surgeons and anesthesiologists. In
patients who had undergone CEA, both regional and gen-
eral anesthesia were used. The technique was chosen ac-
cording to the vascular surgeons’ and anesthesiologists’
preferences. General anesthesia was performed with propo-
fol, sufentanyl, atracurium, and isoflurane. Regional anes-
thesia included the combined cervical block technique de-
scribed elsewhere.17
In patients who had undergone CAS, a percutaneous
femoral approach was routinely used. Local anesthesia of
the groin was performed with lidocaine 1%, without any
additional sedation. Cardiovascular monitoring was per-
formed with a 5 lead-ECG and continuous intra-arterial
blood pressure measurements.
Hemodynamic instability was defined as a pulse rate of
less than 40 beats/min or greater than 100 beats/min, ablood pressure variation of  30% of the preoperative
systolic pressure, or both.
Contrary to other institutions,8 atropine was not in-
jected systematically but only in cases of extreme bradycar-
dia (pulse rate 40 beats/min). Ephedrine, neosyneph-
rine, and norepinephrine were used in case of a decrease in
blood pressure of greater than 30% compared with the
preoperative value. Nicardipine or -blockers were used
when the blood pressure exceeded 30% of the preoperative
value. Doses of 50 and 100 U/kg body weight of heparin
were injected in patients undergoing CEA and CAS, re-
spectively. Postoperatively, all patients were monitored in
the postanesthesia care unit for at least 6 hours.
Postoperative management. All patients were fol-
lowed for at least 1 night in the vascular intensive care unit
by means of continuous 5-lead ECG, invasive blood pres-
sure measurements, oxygen saturation monitoring, and
neurological assessment. ECG was repeated every day for 3
postoperative days.
Patients undergoing CAS were prescribed clopidogrel
(75 mg/d) and aspirin (100 mg/d) for 1 month and then
one antiplatelet drug thereafter,18 and patients undergoing
CEA were started on low-molecular-weight heparin for 48
hours and then aspirin (100 mg/d).
Statistical analysis. The sample size was chosen on
the basis of previous rate of significant increase in CTnI in
patients undergoing vascular surgery (10%-12%).14 Statis-
tical analysis was performed with Statistica version 5 (Tulsa,
Okla).
Values are presented as means  SD. The following
tests were used when appropriate: Student t test, Mann-
Whitney U test, 2 test, and Fisher exact test. Actuarial
survival curves (freedom frommajor cardiac events, includ-
ing the short-term events) were calculated with the Kaplan-
Meier method and compared with the log-rank test. The
status of patients lost to follow-up was considered until
their last visit. Logistic regression was performed to detect
a possible significant influence of the following factors,
which are presumed to affect cardiac morbidity: age greater
than 75 years, hemodynamic instability, -blockade, anti-
platelet therapy, and general anesthesia. The Cox regres-
sion hazard model was used to adjust the baseline value of
survival with the inclusion of factors significantly affecting
major cardiac events.
A P value of less than .05 was considered statistically
significant.
RESULTS
There were not any statistically significant differences in
demographic characteristics between the 2 groups (Table I).
Early postprocedural events. A significant CTnI in-
crease (0.5 ng/mL) was more frequent in the patients
undergoing CEA (13%) when compared with the patients
undergoing CAS (1%; P  .02). All CTnI increases oc-
curred within the 24 first postoperative hours.
In the CEA group 4 of 10 patients had an MI, with
CTnI levels of greater than 0.15 ng/mL associated with
ECG changes (Q-waveMI). The patients in the CAS group
nt; AS
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current series no patient presented with non-Q-wave MI.
No significant correlation was found between peripro-
cedural hemodynamic instability and increase of troponin
levels.
Nonischemic cardiac complications are listed in Table II.
There were no deaths in the CAS group. One patient in
the CEA group died on day 8 from an acute mesenteric
infarct.
Finally, none of these patients experienced stroke or
transient ischemic attack during the first 30 postoperative
days.
Late postprocedural events. The mean time of fol-
low-up was 44  12 months. Twelve (8%) patients were
followed for an average of 36 months and then lost to
follow-up. Four were in the CAS group, and 8 were in the
CEA group. They were not considered for the late outcome
crude calculation but were included in the Kaplan-Meier
curve analysis and the log-rank test. During this period, 2
Table I. Patients characteristics
CEA
Age, mean  SD (y)
Age 75 y (n)
Sex (female/male)
ASA (II/III)
Body mass index (kg/m2)
Prior cardiac risk factor
Hypertension
Diabetes
History of tobacco use
History of myocardial infarction
Prior CABG or coronary stenting
Congestive heart failure
Cardiac rhythm abnormalities
Preoperative cardiac medications
-Blockade
Antiplatelets (aspirin, clopidogrel, or both)
Carotid stenosis with neurologic symptoms
General anesthesia
CEA, Carotid endarterectomy; CAS, carotid angioplasty and stent placeme
tery bypass grafting.
Table II. Periprocedural cardiac complications
CEA, n
Asystole 15 s, severe bradycardia
during the procedure, or both (n)
8
Hypotension during procedure 21
Hypertension during procedure 12
Postoperative hypotension 9
Postoperative hypertension 14
CTnI 0.5 ng/mL 10
CTnI 1.5 ng/mL 4
Cardiac failure 3
Supraventricular arrhythmia 6
Ventricular arrhythmia 4
CEA, Carotid endarterectomy; CAS, carotid angioplasty and stent placemepatients (1 in each group) died of stroke.The accuracy of these events were verified in 89%
(122/138) from hospital records, in 8% (12/138) from
cardiologists’ and/or general practitioners’ letter or inter-
views, and 3% (4/138) from patients and family interviews
alone.
Long-term cardiac events. The incidence of long-
term major cardiac events (MI or death of cardiac origin)
was significantly higher in the CEA group (20% vs 5%, P
.01). No significant difference was noted for minor cardiac
events (Table III).
Kaplan-Meier analysis of survival (freedom from major
cardiac events) is presented in the Figure. The patients
undergoing CAS had a significantly lower incidence of
major cardiac events and death of cardiac origin (2 
8.75, P  .003, hazard ratio  5.3 [95% confidence
interval  1.66-12.2]).
Logistic regression analysis could not detect any statis-
tically significant association between the absence of peri-
operative -blockade, the absence of antiplatelet therapy,
75 (%) CAS, n  75 (%) P value
11 70  10 .32
21 .6
63 16/59 .27
41 37/38 .66
2 25  2 .8
7) 62 (82) .38
8) 10 (13) .43
3) 37 (49) .18
6) 10 (13) .8
3) 9 (12) .9
) 7 (9.3) .9
4.6) 6 (8) .25
3) 43 (57) .6
9) 65 (86) .14
6) 38 (51) .57
2) 2 (2.6) .01
A, American Society of Anesthesiologist classification;CABG, coronary ar-
5 (%) CAS, n  75 (%) P value
35 (46) .001
3 (4) .001
2 (2.6) .001
21 (28) .004
3 (4) .002
) 1 (1.3) .001
1 (1.3) .2
1 (1.3) .36
3 (4) .37
1 (1.3) .2
nI, cardiac troponin I., n 
72 
20
12/
34/
25 
58 (7
14 (1
40 (5
12 (1
10 (1
6 (8
11 (1
40 (5
52 (6
42 (5
39 (5 7
(10)
(28)
(16)
(12)
(18)
(13.3
(5.3)
(4)
(8)
(5.3)and the presence of general anesthesia with major cardiac
fidenc
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association with these events (P  .04). However, this
factor did not alter significantly the hazard ratio and the
general trend observed between groups after adjustment
(P 0.02; hazard ratio 7.78, as assessed bymeans of Cox
regression analysis).
DISCUSSION
This study shows that the incidence of CTnI increase
after CEA was more frequent when compared with that
seen in a similar population who underwent CAS. Further-
more, the incidence of major cardiac events in the long
term was higher in the CEA group.
There was not any significant relationship between hemo-
dynamic instability and troponin increase in the periproce-
dural period. However, the sample size might not be appro-
Freedom frommajor cardiac events and death of cardiac o
test: 2  8.75, P  .003, hazard ratio  5.3 (95% con
Table III. Logistic regression analysis assessing the effect
of several factors that could have an effect on major
cardiac events
2 P value
Age 75 y 2.2 .04
Periprocedural hypertension 0.5 .5
Periprocedural hypotension 0.7 .4
-Blockade 1.2 .6
Antiplatelet therapy 1.44 .62
General anesthesia 1.6 .4priate to comment strictly on our findings. The incidence ofmyocardial ischemia and MI in our group of patients under-
going CEA was slightly higher in comparison with those
previously reported.19-24 This might be related to the single-
center nature of our study and the fact that preoperative
-blockade and antiplatelet therapy were not universal at this
time point; however, a higher incidence, especially after 5
years, has been described.25-27 Moreover, CTnI is much more
sensitive than ECG, creatine phosphokinase MB modifica-
tion, or both28,29 and can partly explain the higher incidence
of myocardial ischemia episodes detected in our group of
patients undergoing CEA. The results of this study are con-
sistent with the results of the SAPPHIRE trial, which is a
larger randomized multicenter trial in selected high-risk pa-
tients. The rate ofMI in the CEA arm (8%) is also higher than
that in the CAS arm (2.5%) in this trial.30-32 However, the
present study is not restricted to high-risk patients.Our results
are also in accordance with the results of previous studies,
which have shown that the occurrence of perioperative MI
increases the risk of major cardiac events in the subsequent
period.15,33,34 Therefore as in the SAPPHIRE trial,32 the
different shape of Kaplan-Meier curves observed in our study
could be strongly related to the delayed effect of perioperative
MI. Nevertheless, the data of this study are insufficient to
assess whether an increase inCTnI levels, especially when they
are between 0.5 and 1.5 ng/mL, has a significant prognostic
value to predict long-term major cardiac complications.
Our long-term results should be interpreted cautiously
because despite the fact that there was no significant differ-
ence in demographic characteristics, the overall long-term
.Mean time of follow-up was 44 12months. Log-rank
e interval  1.66-12.2).riginmortality was significantly higher in the CEA group, and
nt.
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difference. It should also be noted that the statistical signif-
icance for major cardiac events was obtained only by pool-
ing cardiac death and nonfatal MI.
The other limitations of this study include a group
assignment on the basis of surgical and anatomic factors
rather than a classic randomization procedure and a limited
number of patients, which do not permit us to integrate all
factors into a multivariate model. In addition, as an impor-
tant factor, general anesthesia was poorly balanced between
the 2 arms because only 2 patients in the CAS group had
general anesthesia. However, the superiority of regional
anesthesia concerning the major cardiac events, especially
in carotid surgery, is not documented. Despite these short-
comings, the increase in CTnI levels is an objective mea-
surement of ischemic injury of the heart and a reliable
predictor of cardiac morbidity in the short-term and mid-
term postoperative periods (6 months).12-14 Another pos-
sible factor that could explain partly the difference between
the 2 procedures might be the fact that all patients in the
CAS group had clopidogrel associated with aspirin in the
first month, whereas this combination was not systemati-
cally administered in the CEA arm (Table IV). Neverthe-
less, it is unlikely that this difference could affect early
outcome because almost all early cardiac complications
occurred in the first postprocedural day, whereas for late
outcomes, treatments were similar. Because of the peripro-
cedural hemodynamic instability in the CEA group but also
in the CAS group, routine dosage of CTnI and intensive
care monitoring of high-risk patients should be dis-
cussed.35-37 Future randomized controlled studies should
also evaluate the short- and long-term cardiac outcomes of
these procedures (Table IV).
We thank Dr Murat Aksoy, who kindly reviewed the
manuscript.
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